Comparative Pharmacology
Head-to-head clinical analysis: VANCOCIN HYDROCHLORIDE versus VANCOMYCIN HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VANCOCIN HYDROCHLORIDE versus VANCOMYCIN HCL.
VANCOCIN HYDROCHLORIDE vs VANCOMYCIN HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vancomycin inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of cell wall precursor units, thereby preventing polymerization and cross-linking of peptidoglycan.
Inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, preventing cross-linking and polymerization.
15-20 mg/kg IV every 8-12 hours; maximum single dose 2 g. Target trough 10-20 mcg/mL.
15-20 mg/kg IV every 8-12 hours (max 2 g/dose) for serious infections; target trough 15-20 mcg/mL.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults with normal renal function; prolonged to 7-9 days in anuric patients, necessitating therapeutic drug monitoring.
4-6 hours in normal renal function; prolonged to 7-9 days in anuria/ESRD, necessitating dosing adjustments
Primarily renal (glomerular filtration): 80-90% of dose excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination (<5%).
Primarily renal (90-95% unchanged via glomerular filtration), with minor biliary/fecal (<5%)
Category C
Category A/B
Glycopeptide Antibiotic
Glycopeptide Antibiotic